CYBN Share Price Performance
US$5.85
-3.97 (-40.43%)
Price US$5.85
BrightSide
Share PriceUS$5.85
Cybin Inc. Stock Price
- 1 Narratives written by author
- 1 Comments on narratives written by author
- 46 Fair Values set on narratives written by author
CYBN Community Narratives
BR
Fair Value US$0 n/aintrinsic discount
Cybin will leverage its 70 patents for breakthroughs in holistic depression treatment
1users have liked this narrative
1users have commented on this narrative
8users have followed this narrative
Recent CYBN News & Updates
Cybin Inc. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -3.84
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 29.3%
Cybin Inc. Competitors
Snowflake Analysis
About CYBN
- Founded
- n/a
- Employees
- 50
- CEO
- WebsiteView website
Cybin Inc., a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company also develops SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat central nervous system, as well as has a research pipeline of investigational psychedelic-based compounds. It has a strategic partnership agreement with Segal Trials to support PARADIGM, a multinational pivotal phase 3 program evaluating CYB003 for the adjunctive treatment of major depressive disorder. The company is headquartered in Toronto, Canada.
Market Insight
Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading
Canadian Market Performance
- 7 Days: -1.7%
- 3 Months: 8.6%
- 1 Year: 18.8%
- Year to Date: 18.4%
Over the last 7 days, the market has dropped 1.7%, driven by a loss of 2.1% in the Financials sector. In the last year, the market is actually up 19%. As for the next few years, earnings are expected to grow by 11% per annum. Market details ›